AXIOS June 28, 2024
It’s pretty clear at this point that the latest class of Alzheimer’s drugs — for all of the headlines, excitement and controversy it’s caused — has limited effectiveness and potentially serious side effects, prompting researchers to look elsewhere.
Why it matters: The fact that we’ve found drugs with any effectiveness against Alzheimer’s is a huge deal, but the hunt for the holy grail is still on.
- Eli Lilly’s drug candidate donanemab could soon become the third anti-amyloid monoclonal antibody — which targets a buildup of proteins in the brain thought to contribute to Alzheimer’s — to receive some kind of FDA approval, all in the past three years.
- “Donanemab and related drugs caused a splash. But I think that...
Today's Sponsors
Today's Sponsor